Loading…
CADL
Candel Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology
$13.07-4.95%
Key metrics
- Market cap
- $1B
- P/E
- —
- Forward P/E
- —
- P/B
- 7.9x
- Dividend yield
- —
- EPS
- -$1.47
- ROE
- -81.84%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.50
- 52-week high
- $14.00
- 52-week low
- $4.35
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
- 55
- Needham, United States
Company description provided by Yahoo Finance.